BioCryst Pharmaceuticals
As of the edition of 20 October 2026, BioCryst Pharmaceuticals runs 16 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Astria Therapeutics, Inc.: acquired in 2026; successor BioCryst Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals: acquired in 2026; successor BioCryst Pharmaceuticals, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Went quiet | 5 |
| Stopped | 4 |
| Status not established | 2 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Peramivir anhydrous | none listed | 0 |
| Forodesine | none listed | 0 |
| Berotralstat | Ends 2039 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| KLKB1 Plasma kallikrein | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where BioCryst Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 32 trials led
- Inherited and neonatal: 30 trials led
- Skin and connective tissue: 22 trials led